Ocuphire Pharma Inc Forecast, price target & analysts
Ocuphire Pharma Inc Target price 2025 - Analyst rating & recommendation
Ocuphire Pharma Inc Classifications & Recommendation:
Ocuphire Pharma Inc Price Target
| Target Price | $8.16 |
| Price | $2.04 |
| Potential |
300.00%
register free of charge
|
| Number of Estimates | 10 |
|
10 Analysts have issued a price target Ocuphire Pharma Inc 2026 .
The average Ocuphire Pharma Inc target price is $8.16.
This is
300.00%
register free of charge
$9.45
363.24%
register free of charge
$6.06
197.06%
register free of charge
|
|
| A rating was issued by 12 analysts: 11 Analysts recommend Ocuphire Pharma Inc to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Ocuphire Pharma Inc stock has an average upside potential 2026 of
300.00%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 10.99 | 13.49 |
| 42.31% | 22.72% | |
| EBITDA Margin | -285.35% | 65.15% |
| 535.04% | 122.83% | |
| Net Margin | -523.48% | -331.35% |
| 898.22% | 36.70% |
11 Analysts have issued a sales forecast Ocuphire Pharma Inc 2025 . The average Ocuphire Pharma Inc sales estimate is
This results in the following potential growth metrics:
2 Analysts have issued an Ocuphire Pharma Inc EBITDA forecast 2025. The average Ocuphire Pharma Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
11 Ocuphire Pharma Inc Analysts have issued a net profit forecast 2025. The average Ocuphire Pharma Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -2.15 | -0.69 |
| 367.39% | 67.91% | |
| P/E | negative | |
| EV/Sales | 8.23 |
11 Analysts have issued a Ocuphire Pharma Inc forecast for earnings per share. The average Ocuphire Pharma Inc EPS is
This results in the following potential growth metrics and future valuations:
Ocuphire Pharma Inc...
Current Ocuphire Pharma Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| B. Riley Securities |
Locked
➜
Locked
|
Locked | Dec 10 2025 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | Nov 25 2025 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | Nov 13 2025 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | Nov 07 2025 |
| Wedbush |
Locked
➜
Locked
|
Locked | Oct 29 2025 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | Oct 16 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jun 27 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
B. Riley Securities:
Locked
➜
Locked
|
Dec 10 2025 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Nov 25 2025 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
Nov 13 2025 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
Nov 07 2025 |
|
Locked
Wedbush:
Locked
➜
Locked
|
Oct 29 2025 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
Oct 16 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jun 27 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
